A Phase 2 interventional study of GSK2251052 and imipenem-cilastatin in Infections, Urinary Tract, sponsored by GlaxoSmithKline. Terminated at 24 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-09-08.
Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Urinary Tract Infections by GlaxoSmithKline — 4 open to participants now, 4 under way, none of them phase 3. Urinary Tract Infections · GlaxoSmithKline.
Among the 14 studies in Urinary Tract Infections by GlaxoSmithKline, this one is the 12th largest by enrollment of the 13 interventional ones that give a count, is the only one that started in 2011, is one of 2 in phase 2, and was the 1st registered.
804 studies on the registry are indexed under Urinary Tract Infections; 133 are open to participants now.
Browse Urinary Tract Infections studies →4 of the 14 studies in Urinary Tract Infections by GlaxoSmithKline are open now, in 2 countries. Recruiting first, the newest first:
GlaxoSmithKline · Sites in United States
Ages 18–50 · Women only · Healthy volunteers
GlaxoSmithKline · Sites in United States, South Africa
Ages 18–64 · Healthy volunteers
GlaxoSmithKline
Ages 15–50 · Women only
GlaxoSmithKline · Sites in United States
Ages 2–11
By country, each count listing its studies:
Of the 84 Urinary Tract Infections studies recruiting now, 50 (60%) set no upper age limit and 23 (27%) stop at 75 or younger; 15 take children under 18; 17 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 3 · Phase 3 4 · Phase 4 1
First in 2011; this study’s year is marked. 1 started in 2011.
This study's enrollment of 20 is below the median of 132 across 561 interventional studies indexed under Urinary Tract Infections.
Median enrollment 61 across the 13 interventional studies, 614 across the 1 observational. Of the 10 that completed or were terminated, 9 (90%) have results posted.
This tab as a report to print or save as PDF → With an account.
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
3 of the studies in Urinary Tract Infections by GlaxoSmithKline that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07645235GlaxoSmithKlineA Study to Evaluate Gepotidacin Exposure in Breast Milk of Healthy Lactating Women | 2027-05-17 |
| NCT06702449GlaxoSmithKlineA Study on the Safety and Immune Response of a Urinary Tract Infection (UTI) Vaccine in Adults 18-64 Years of Age and Clinical Efficacy in Females 18-64 Years of Age | 2027-05-31 |
| NCT07371429GlaxoSmithKlineA Study in Pediatric Participants Aged ≥2 to <12 Years With a Suspected or Confirmed Bacterial Infection or Receiving Prophylaxis Antibiotics | 2027-08-23 |
Add all 3 to your calendar (.ics) → With an account.
Among the 14 studies in Urinary Tract Infections by GlaxoSmithKline, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is being conducted to evaluate the safety, efficacy (clinical and microbiological), pharmacokinetics/pharmacodynamics of GSK2251052 and to assess whether it would be a suitable antibiotic for the treatment for febrile lower cUTI and pyelonephritis(complicated and uncomplicated). GSK2251052 will be compared to imipenem-cilastatin, which is an antibiotic commonly used to treat serious cUTI infections. GSK2251052 has a spectrum of microbiological activity that includes pathogens responsible for cUTI.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
N.B. Females of non-childbearing or may be enrolled. Females of childbearing potential must have a negative pregnancy test at study entry and must have practiced adequate for at least 30 days prior to study entry. Additionally, the subject agrees to one of the following methods for avoidance of pregnancy during the entire study treatment period:
Subjects meeting any of the following criteria must not be enrolled in the study:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
q12h administered via IV infusion, plus saline placebo
Drug: GSK2251052 · Other: Placebo
q12h administered via IV infusion, plus saline placebo
Drug: GSK2251052 · Other: Placebo
500 mg imipenem monohydrate and 500 mg cilastatin sodium; q6h administered via IV infusion, plus saline placebo
Drug: imipenem-cilastatin · Other: Placebo
Reconstituted, added to 250mL 0.9% NaCl solution and administered via IV infusion
Prepare as per prescribing information instructions in 100 mL bag of 0.9% NaCl and administered via IV infusion
Also known as: Primaxin® (Manufacturer: Merck)
saline placebo
Change From Baseline in Clinical Laboratory Parameters- Albumin and Total Protein
Clinical laboratory parameters included albumin and total protein. Baseline was Day 1. Change from Baseline was calculated by subtracting Baseline values from individual post-Baseline values. Mean change from Baseline up to Late follow-up visit in albumin and total protein are presented.
Time frame: Baseline (Day 1) to Late Follow up Visit (21 to 28 days post-IV therapy)
Change From Baseline in Clinical Laboratory Parameters- Creatinine Clearance, Estimated (CCE)
Clinical laboratory parameters included CCE. Baseline was Day 1. Change from Baseline was calculated by subtracting Baseline values from individual post-Baseline values. Mean change from Baseline up to Late follow-up visit in CCE are presented.
Time frame: Baseline (Day 1) to Late Follow up Visit (21 to 28 days post-IV therapy)
Change From Baseline in Clinical Laboratory Parameters- Creatinine, Direct Bilirubin and Total Bilirubin
Clinical laboratory parameters included creatinine, direct bilirubin and total bilirubin. Baseline was Day 1. Change from Baseline was calculated by subtracting Baseline values from individual post-Baseline values. Mean change from Baseline up to Late follow-up visit in creatinine, direct bilirubin and total bilirubin are presented.
Time frame: Baseline (Day 1) to Late Follow up Visit (21 to 28 days post-IV therapy)
Change From Baseline in Clinical Laboratory Parameters- Calcium, Carbon-dioxide (C02) Content/Bicarbonate, Chloride, Glucose, Potassium, Sodium and Urea/Blood Urea Nitrogen (BUN)
Clinical laboratory parameters included C02 content/bicarbonate, chloride, glucose, potassium, sodium and urea/BUN. Baseline was Day 1. Change from Baseline was calculated by subtracting Baseline values from individual post-Baseline values. Mean change from Baseline up to Late follow-up visit in C02 content/bicarbonate, chloride, glucose, potassium, sodium and urea/BUN are presented.
Time frame: Baseline (Day 1) to Late Follow up Visit (21 to 28 days post-IV therapy)
Change From Baseline in Clinical Laboratory Parameters- Alanine Amino Transferase (ALT), Alkaline Phosphatase (ALP), Aspartate Amino Transferase (AST), Creatine Kinase and Gamma Glutamyl Transferase (GGT)
Clinical laboratory parameters included ALT, ALP, AST, Creatine kinase and GGT. Baseline was Day 1. Change from Baseline was calculated by subtracting Baseline values from individual post-Baseline values. Mean change from Baseline up to Late follow-up visit in ALT, ALP, AST, Creatine kinase and GGT are presented.
Time frame: Baseline (Day 1) to Late Follow up Visit (21 to 28 days post-IV therapy)
Number of Participants With Adverse Events (AE) and Serious Adverse Events (SAE)
AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. For marketed medicinal products, this also includes failure to produce expected benefits (i.e., lack of efficacy), abuse or misuse. SAE is any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect or is medically significant.
Time frame: Up to 28 days post-therapy
Number of Participants With Abnormal Electrocardiogram (ECG) Findings
Twelve lead ECGs were obtained during the study using an ECG machine that automatically measured PR, QRS, QT, and QT corrected by Bazett's formula (QTcB), QT corrected by Fridericia's formula (QTcF) intervals. Twelve lead ECGs were performed with the participant in a semi-supine position having rested in this position for at least 10 minutes beforehand. Measurements that deviated substantially from previous readings were repeated immediately. Three measurements were taken at pre-dose on Day 1 at least 5 min apart. One additional ECG measurement was taken after completion of the first infusion of study medication. Two ECG measurements (pre and post-1st infusion of the day) were taken on Day 4 while the participant was on IV therapy. When there was an abnormal finding, two more were taken and the mean PR interval, QRS duration, QT interval and QTcB were calculated from automated ECG readings. One ECG measurement was taken at the early safety follow-up visit.
Time frame: Up to Late Follow-up Visit (21 to 28 days post-IV therapy)
Summary of Vital Signs: Mean Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)
Vital sign measurements included SBP and DBP (supine or semi-supine). Measurements that deviated substantially from previous readings were repeated immediately. Mean SBP and DBP are presented.
Time frame: Up to Late Follow up Visit (21 to 28 days post-IV therapy)
Summary of Vital Signs- Mean Heart Rate
Vital sign measurements included heart rate. Measurements that deviated substantially from previous readings were repeated immediately. Mean heart rate is presented.
Time frame: Up to Late Follow-up Visit (21 to 28 days post-IV therapy)
Summary of Vital Signs- Mean Respiration Rate
Vital sign measurements included respiratory rate. Measurements that deviated substantially from previous readings were repeated immediately. Mean respiration rate are presented.
Time frame: Up to Late Follow-up Visit (21 to 28 days post-IV therapy)
Summary of Vital Signs- Mean Temperature
Vital sign measurements included temperature (oral, tympanic or rectal). Measurements that deviated substantially from previous readings were repeated immediately. Temperature was assessed as normal hospital practice dictated and the maximum daily temperature was recorded in the electronic case report form (eCRF).
Time frame: Up to Late Follow up Visit (21 to 28 days post-IV therapy)
Therapeutic Response at the Test of Cure Visit
The therapeutic response was the combination of a participant's clinical and microbiological response. It was assessed at the Test of Cure visit in participants who have a qualifying Gram-negative uropathogen at Baseline and have had a minimum of 5 days of IV therapy. Therapeutic response was a measure of the overall efficacy response, and a therapeutic success referred to participants who have been deemed both a 'clinical success' and a 'microbiological success'. All other combinations (other than 'clinical success' + 'microbiological success') were deemed failures for therapeutic response.
Time frame: Test of Cure Visit (5 to 9 days post-IV therapy)
Change From Baseline in Hematology Parameters- Hematocrit
Hematology parameters included hematocrit. Baseline was Day 1. Change from Baseline was calculated by subtracting Baseline values from individual post-Baseline values. Mean change from Baseline up to Late follow-up visit in hematocrit are presented.
Time frame: Baseline (Day 1) to Late Follow up Visit (21 to 28 days post-IV therapy)
Change From Baseline in Hematology Parameters- Mean Corpuscle Hemoglobin (MCH)
Hematology parameters included MCH. Baseline was Day 1. Change from Baseline was calculated by subtracting Baseline values from individual post-Baseline values. Mean change from Baseline up to Late follow-up visit in MCH are presented.
Time frame: Baseline (Day 1) to Late Follow up Visit (21 to 28 days post-IV therapy)
Change From Baseline in Hematology Parameters- Mean Corpuscle Volume (MCV)
Hematology parameters included MCV. Baseline was Day 1. Change from Baseline was calculated by subtracting Baseline values from individual post-Baseline values. Mean change from Baseline up to Late follow-up visit in MCV are presented.
Time frame: Baseline (Day 1) to Late Follow up Visit (21 to 28 days post-IV therapy)
Change From Baseline in Hematology Parameters- Red Blood Cell (RBC) Count and Reticulocytes
Hematology parameters included RBC count and reticulocytes. Baseline was Day 1. Change from Baseline was calculated by subtracting Baseline values from individual post-Baseline values. Mean change from Baseline up to Late follow-up visit in RBC count and reticulocytes are presented.
Time frame: Baseline (Day 1) to Late Follow up Visit (21 to 28 days post-IV therapy)
Change From Baseline in Hematology Parameters- Hemoglobin and Mean Corpuscle Hemoglobin Concentration (MCHC)
Hematology parameters included hemoglobin and MCHC. Baseline was Day 1. Change from Baseline was calculated by subtracting Baseline values from individual post-Baseline values. Mean change from Baseline up to Late follow-up visit in hemoglobin and MCHC are presented.
Time frame: Baseline (Day 1) to Late Follow up Visit (21 to 28 days post-IV therapy)
Change From Baseline in Hematology Parameters- Basophils, Eosinophils, Lymphocytes, Monocytes, Platelet Count, Total Neutrophils and White Blood Cell Count (WBC)
Hematology parameters included basophils, eosinophils, lymphocytes, monocytes, platelet count, total neutrophils and WBC. Baseline was Day 1. Change from Baseline was calculated by subtracting Baseline values from individual post-Baseline values. Mean change from Baseline up to Late follow-up visit in basophils, eosinophils, lymphocytes, monocytes, platelet count, total neutrophils and WBC are presented.
Time frame: Baseline (Day 1) to Late Follow up Visit (21 to 28 days post-IV therapy)
Microbiological Response at the End of IV Therapy Visit, Test of Cure Visit and Late Follow-Up Visit
Microbiological response involved both microbiological success and microbiological failure. A reduction in the uropathogens in the urine culture and no growth on blood culture was termed as microbiological success. Increase in the uropathogens in the urine culture and pathogens identified in the blood culture or use of antibacterials other than study treatments were classified as microbiological failures.
Time frame: End of IV therapy (0-24 hours post-therapy), Test of Cure Visit (5 to 9 days post-IV therapy) and Late Follow-up (21-28 days post-therapy)
Clinical Response at the End of IV Therapy Visit, Test of Cure Visit and Late Follow-Up Visit
Clinical response was a combination of clinical success and clinical failure. In clinical success, participants showed no signs and symptoms of pyelonephritis and lower complicated urinary tract infection and antibiotics are not used for the same. In clinical failure, there is reappearance of signs and symptoms of and lower complicated urinary tract infection and participant required antibiotics for the same.
Time frame: End of IV therapy (0-24 hours post-therapy), Test of Cure Visit (5 to 9 days post-IV therapy) and Late Follow-up (21-28 days post-therapy)
Therapeutic Response (Combined Clinical and Microbiological Response) at the End of IV Visit and Late Follow-Up Visit
The therapeutic response was the combination of a participant's clinical and microbiological response. It was assessed at the Test of Cure visit in participants who have a qualifying Gram-negative uropathogen at Baseline and have had a minimum of 5 days of IV therapy. Therapeutic response was a measure of the overall efficacy response, and a therapeutic success referred to participants who have been deemed both a 'clinical success' and a 'microbiological success'. All other combinations (other than 'clinical success' + 'microbiological success') were deemed failures for therapeutic response.
Time frame: End of IV therapy (0-24 hours post-therapy) and Late Follow-up (21-28 days post-therapy)
Maximum Plasma Concentration (Cmax) of GSK2251052
The planned pharmacokinetic (PK) and PK/pharmacodynamic analyses were not performed, because the PK data was not collected.
Time frame: Day 3: Pre- dose (just prior to the start of the first infusion of the day) and 1 hour (just prior to the end of the infusion), 2, 4, and 12 hours post-dose
Area Under the Concentration Time Curve (AUC) of GSK2251052
The planned pharmacokinetic (PK) and PK/pharmacodynamic analyses were not performed, because the PK data was not collected.
Time frame: Day 3: Pre- dose (just prior to the start of the first infusion of the day) and 1 hour (just prior to the end of the infusion), 2, 4, and 12 hours post-dose
Time to Cmax (Tmax) of GSK2251052
The planned pharmacokinetic (PK) and PK/pharmacodynamic analyses were not performed, because the PK data was not collected.
Time frame: Day 3: Pre- dose (just prior to the start of the first infusion of the day) and 1 hour (just prior to the end of the infusion), 2, 4, and 12 hours post-dose
Cmax of GSK2251052 Using Non-intensive PK Sampling
The planned pharmacokinetic (PK) and PK/pharmacodynamic analyses were not performed, because the PK data was not collected.
Time frame: Day 4: Pre- dose (just prior to the start of the first infusion of the day) and 1 hour (just prior to the end of the infusion), 2, 4, and 12 hours post-dose
AUC of GSK2251052 Using Non-intensive PK Sampling
The planned pharmacokinetic (PK) and PK/pharmacodynamic analyses were not performed, because the PK data was not collected.
Time frame: Day 4: Pre- dose (just prior to the start of the first infusion of the day) and 1 hour (just prior to the end of the infusion), 2, 4, and 12 hours post-dose
Tmax of GSK2251052 Using Non-intensive PK Sampling
The planned pharmacokinetic (PK) and PK/pharmacodynamic analyses were not performed, because the PK data was not collected.
Time frame: Day 4: Pre- dose (just prior to the start of the first infusion of the day) and 1 hour (just prior to the end of the infusion), 2, 4, and 12 hours post-dose
Cmax of GSK2251052 Using Intensive PK Sampling
The planned pharmacokinetic (PK) and PK/pharmacodynamic analyses were not performed, because the PK data was not collected.
Time frame: Day 4: Pre-dose (just prior to the start of the first infusion of the day) 0.5, 1 hour (just prior to the end of the infusion), 1.25, 1.5, 2, 3, 4, 8 and 12 hours post-dose
AUC of GSK2251052 Using Intensive PK Sampling
The planned pharmacokinetic (PK) and PK/pharmacodynamic analyses were not performed, because the PK data was not collected.
Time frame: Day 4: Pre-dose (just prior to the start of the first infusion of the day) 0.5, 1 hour (just prior to the end of the infusion), 1.25, 1.5, 2, 3, 4, 8 and 12 hours post-dose
Tmax of GSK2251052 Using Intensive PK Sampling
The planned pharmacokinetic (PK) and PK/pharmacodynamic analyses were not performed, because the PK data was not collected.
Time frame: Day 4: Pre-dose (just prior to the start of the first infusion of the day) 0.5, 1 hour (just prior to the end of the infusion), 1.25, 1.5, 2, 3, 4, 8 and 12 hours post-dose
This study was conducted at eight centers in three countries (United States, Spain and Greece) from 28-June-2011 to 06-March-2012. A total of 20 participants were randomized in the study.
| Milestone | GSK2251052 750 mg | GSK2251052 1500 mg | Imipenem-Cilastatin |
|---|---|---|---|
| Started | 6 | 8 | 6 |
| Completed | 6 | 8 | 5 |
| Not completed | 0 | 0 | 1 |
| Withdrew: Ineligible: no organisms isolated | 0 | 0 | 1 |
Clinical laboratory parameters included albumin and total protein. Baseline was Day 1. Change from Baseline was calculated by subtracting Baseline values from individual post-Baseline values. Mean change from Baseline up to Late follow-up visit in albumin and total protein are presented.
| Gram per Liter | GSK2251052 750 mg | GSK2251052 1500 mg | Imipenem-Cilastatin |
|---|---|---|---|
| Albumin: On IV therapy (Day 5) | -0.5 ± 4.85 | -3.8 ± 7.09 | -0.3 ± 3.06 |
| Albumin: On IV therapy (Day 11) | 2.0 ± NA | — | — |
| Albumin: End of IV therapy | 1.0 ± 4.69 | -2.1 ± 7.38 | 0.8 ± 3.31 |
| Albumin: Test of Cure | 5.7 ± 3.67 | 1.7 ± 5.79 | 2.6 ± 2.61 |
| Albumin: Early Follow-up | 8.2 ± 2.77 | 3.5 ± 3.39 | 3.4 ± 3.65 |
| Albumin: Late Follow-up | 7.3 ± 4.93 | 3.5 ± 4.59 | 3.2 ± 3.77 |
| Total protein: On IV therapy (Day 5) | 0.0 ± 8.17 | -5.0 ± 9.09 | 1.0 ± 6.24 |
| Total protein: On IV therapy (Day 11) | -5.0 ± NA | — | — |
| Total protein: End of IV therapy | -0.4 ± 9.76 | -3.3 ± 10.14 | 3.0 ± 6.69 |
| Total protein: Test of Cure | 5.8 ± 7.68 | 2.1 ± 6.89 | 6.4 ± 3.29 |
| Total protein: Early Follow-up | 9.4 ± 5.13 | 5.3 ± 3.27 | 6.4 ± 4.98 |
| Total protein: Late Follow-up | 8.2 ± 4.92 | 5.3 ± 6.28 | 4.8 ± 5.40 |
Clinical laboratory parameters included CCE. Baseline was Day 1. Change from Baseline was calculated by subtracting Baseline values from individual post-Baseline values. Mean change from Baseline up to Late follow-up visit in CCE are presented.
| Milliliter per minute | GSK2251052 750 mg | GSK2251052 1500 mg | Imipenem-Cilastatin |
|---|---|---|---|
| CCE: On IV therapy (Day 5) | — | 18.0 ± NA | — |
| CCE: Test of Cure | 2.0 ± NA | 13.0 ± NA | 56.0 ± NA |
| CCE: Early Follow-up | 1.0 ± NA | 21.0 ± NA | 60.0 ± NA |
| CCE: Late Follow-up | 25.0 ± NA | 21.0 ± NA | — |
Clinical laboratory parameters included creatinine, direct bilirubin and total bilirubin. Baseline was Day 1. Change from Baseline was calculated by subtracting Baseline values from individual post-Baseline values. Mean change from Baseline up to Late follow-up visit in creatinine, direct bilirubin and total bilirubin are presented.
| Micromole per liter | GSK2251052 750 mg | GSK2251052 1500 mg | Imipenem-Cilastatin |
|---|---|---|---|
| Creatinine: On IV therapy (Day 5) | -4.20 ± 10.347 | -5.78 ± 13.336 | -11.97 ± 10.279 |
| Creatinine: On IV therapy (Day 11) | -1.50 ± NA | — | — |
| Creatinine: End of IV therapy | -0.24 ± 13.616 | -11.26 ± 12.634 | -8.70 ± 9.426 |
| Creatinine: Test of Cure | -2.17 ± 7.238 | -9.66 ± 11.743 | -8.54 ± 9.816 |
| Creatinine: Early Follow-up | -3.90 ± 6.134 | 2.88 ± 14.662 | -4.56 ± 11.138 |
| Creatinine: Late Follow-up | 4.43 ± 6.960 | -5.22 ± 10.760 | -5.22 ± 11.228 |
| Total bilirubin: On IV therapy (Day 3) | -7.5 ± 10.73 | -4.9 ± 4.45 | -7.2 ± 6.42 |
| Total bilirubin: On IV therapy (Day 5) | -7.0 ± 10.18 | -3.5 ± 5.57 | -7.3 ± 8.50 |
| Total bilirubin: On IV therapy (Day 8) | -5.0 ± NA | -4.5 ± 0.71 | -1.0 ± NA |
| Total bilirubin: On IV therapy (Day 11) | -1.0 ± NA | — | — |
| Total bilirubin: End of IV therapy | -8.2 ± 11.37 | -5.6 ± 0.71 | -5.5 ± 6.16 |
| Total bilirubin: Test of Cure | -7.7 ± 9.14 | -4.7 ± 5.00 | -6.4 ± 7.64 |
| Total bilirubin: Early Follow-up | -6.2 ± 8.29 | -4.5 ± 3.39 | -6.0 ± 7.04 |
| Total bilirubin: Late Follow-up | -5.2 ± 8.73 | -4.8 ± 4.12 | -5.0 ± 4.80 |
Clinical laboratory parameters included C02 content/bicarbonate, chloride, glucose, potassium, sodium and urea/BUN. Baseline was Day 1. Change from Baseline was calculated by subtracting Baseline values from individual post-Baseline values. Mean change from Baseline up to Late follow-up visit in C02 content/bicarbonate, chloride, glucose, potassium, sodium and urea/BUN are presented.
| Millimole per Liter | GSK2251052 750 mg | GSK2251052 1500 mg | Imipenem-Cilastatin |
|---|---|---|---|
| Calcium: On IV therapy (Day 5) | 0.082 ± 0.1664 | -0.112 ± 0.2170 | 0.060 ± 0.1229 |
| Calcium: On IV therapy (Day 11) | 0.030 ± NA | — | — |
| Calcium: End of IV therapy | -0.020 ± 0.2411 | 0.071 ± 0.1964 | 0.078 ± 0.0930 |
| Calcium: Test of Cure | 0.235 ± 0.2627 | 0.096 ± 0.2057 | 0.128 ± 0.1114 |
| Calcium: Early Follow-up | 0.276 ± 0.1383 | 0.120 ± 0.0919 | 0.142 ± 0.1232 |
| Calcium: Late Follow-up | 0.243 ± 0.0922 | 0.115 ± 0.1027 | 0.110 ± 0.1538 |
| C02 content/Bicarbonate: On IV therapy (Day 5) | -1.7 ± 3.01 | 0.0 ± 2.83 | -2.0 ± 0.00 |
| C02 content/Bicarbonate: On IV therapy (Day 11) | -3.0 ± NA | — | — |
| C02 content/Bicarbonate: End of IV therapy | -2.4 ± 2.07 | 0.6 ± 2.30 | -0.3 ± 2.88 |
| C02 content/Bicarbonate: Test of Cure | -0.8 ± 1.72 | 2.7 ± 1.80 | 1.4 ± 4.28 |
| C02 content/Bicarbonate: Early Follow-up | 0.0 ± 3.81 | 0.3 ± 1.63 | -0.4 ± 4.72 |
| C02 content/Bicarbonate: Late Follow-up | 0.7 ± 2.34 | 1.8 ± 2.71 | 1.2 ± 4.97 |
| Chloride: On IV therapy (Day 5) | 1.2 ± 4.07 | 1.8 ± 3.50 | 3.7 ± 1.15 |
| Chloride: On IV therapy (Day 11) | 4.0 ± NA | — | — |
| Chloride: End of IV therapy | 1.0 ± 3.74 | 3.0 ± 3.83 | -0.2 ± 2.32 |
| Chloride: Test of Cure | 0.5 ± 3.94 | 1.0 ± 3.83 | 0.2 ± 2.28 |
| Chloride: Early Follow-up | 0.6 ± 4.72 | 0.5 ± 4.51 | 0.0 ± 2.35 |
| Chloride: Late Follow-up | 0.3 ± 4.18 | -0.5 ± 3.02 | 2.2 ± 0.84 |
| Glucose: On IV therapy (Day 5) | 0.42 ± 1.993 | 2.25 ± 1.700 | -2.00 ± 2.685 |
| Glucose: On IV therapy (Day 11) | 1.50 ± NA | — | — |
| Glucose: End of IV therapy | -1.06 ± 1.372 | 1.09 ± 1.542 | -0.68 ± 2.741 |
| Glucose: Test of Cure | -0.35 ± 1.649 | -0.11 ± 1.173 | -0.24 ± 2.261 |
| Glucose: Early Follow-up | -0.80 ± 1.158 | 0.07 ± 1.316 | -0.78 ± 1.949 |
| Glucose: Late Follow-up | -0.45 ± 1.106 | 0.58 ± 1.703 | -0.56 ± 2.395 |
| Potassium: On IV therapy (Day 5) | 0.52 ± 0.662 | -0.05 ± 0.645 | 0.37 ± 0.666 |
| Potassium: On IV therapy (Day 11) | 0.00 ± NA | — | — |
| Potassium: End of IV therapy | 0.46 ± 0.623 | 0.24 ± 0.509 | 0.48 ± 0.407 |
| Potassium: Test of Cure | 0.78 ± 0.739 | 0.40 ± 0.526 | 0.44 ± 0.351 |
| Potassium: Early Follow-up | 0.40 ± 0.725 | 0.50 ± 0.400 | 0.42 ± 0.327 |
| Potassium: Late Follow-up | 0.28 ± 0.471 | 0.53 ± 0.547 | 0.40 ± 0.495 |
| Sodium: On IV therapy (Day 5) | 1.2 ± 2.23 | 0.3 ± 2.75 | 2.3 ± 2.52 |
| Sodium: On IV therapy (Day 11) | 4.0 ± NA | — | — |
| Sodium: End of IV therapy | 0.4 ± 2.79 | 1.7 ± 3.15 | -0.8 ± 2.14 |
| Sodium: Test of Cure | 1.8 ± 1.33 | 1.3 ± 3.40 | 1.0 ± 1.73 |
| Sodium: Early Follow-up | 1.8 ± 3.27 | -0.5 ± 3.45 | 1.0 ± 1.58 |
| Sodium: Late Follow-up | 1.2 ± 3.54 | -1.2 ± 4.36 | 2.0 ± 2.65 |
| Urea/BUN: On IV therapy (Day 5) | -0.98 ± 2.024 | -0.45 ± 1.515 | -0.97 ± 0.874 |
| Urea/BUN: On IV therapy (Day 11) | -2.50 ± NA | — | — |
| Urea/BUN: End of IV therapy | -0.30 ± 2.633 | -1.13 ± 1.367 | -0.57 ± 1.046 |
| Urea/BUN: Test of Cure | -0.38 ± 1.184 | -0.73 ± 1.456 | -0.38 ± 1.033 |
| Urea/BUN: Early Follow-up | -0.64 ± 1.305 | 0.20 ± 2.262 | -0.34 ± 0.853 |
| Urea/BUN: Late Follow-up | -0.30 ± 0.716 | -0.33 ± 1.199 | -0.12 ± 1.932 |
Clinical laboratory parameters included ALT, ALP, AST, Creatine kinase and GGT. Baseline was Day 1. Change from Baseline was calculated by subtracting Baseline values from individual post-Baseline values. Mean change from Baseline up to Late follow-up visit in ALT, ALP, AST, Creatine kinase and GGT are presented.
| International units per Liter | GSK2251052 750 mg | GSK2251052 1500 mg | Imipenem-Cilastatin |
|---|---|---|---|
| ALT: On IV therapy (Day 3) | 5.7 ± 8.14 | 10.4 ± 21.53 | 12.8 ± 11.19 |
| ALT: On IV therapy (Day 5) | 33.2 ± 46.82 | 4.8 ± 8.85 | 13.3 ± 17.90 |
| ALT: On IV therapy (Day 8) | 4.0 ± NA | 1.5 ± 6.36 | -3.0 ± NA |
| ALT: On IV therapy (Day 11) | 2.0 ± NA | — | — |
| ALT: End of IV therapy | 35.4 ± 40.46 | 18.6 ± 21.35 | 21.3 ± 29.30 |
| ALT: Test of Cure | 17.5 ± 18.53 | 7.3 ± 10.34 | 7.0 ± 10.12 |
| ALT: Early Follow-up | 4.8 ± 5.97 | 1.0 ± 5.33 | 5.8 ± 7.40 |
| ALT: Late Follow-up | 3.3 ± 5.99 | -0.3 ± 4.32 | 4.2 ± 5.50 |
| ALP: On IV therapy (Day 3) | 10.8 ± 26.33 | 14.3 ± 30.12 | 13.2 ± 28.28 |
| ALP: On IV therapy (Day 5) | 11.2 ± 22.99 | 4.0 ± 27.14 | 17.7 ± 35.50 |
| ALP: On IV therapy (Day 8) | -10.0 ± NA | 21.5 ± 12.02 | -10.0 ± NA |
| ALP: On IV therapy (Day 11) | -11.0 ± NA | — | — |
| ALP: End of IV therapy | 7.4 ± 26.28 | 16.3 ± 34.62 | 10.2 ± 22.60 |
| ALP: Test of Cure | 10.8 ± 23.47 | 6.9 ± 15.04 | 14.8 ± 17.01 |
| ALP: Early Follow-up | 7.4 ± 21.01 | 1.2 ± 23.73 | 8.2 ± 12.01 |
| ALP: Late Follow-up | 5.7 ± 20.64 | 2.3 ± 13.81 | 3.6 ± 13.13 |
| AST: On IV therapy (Day 3) | 5.0 ± 12.07 | 4.1 ± 12.58 | 19.2 ± 16.04 |
| AST: On IV therapy (Day 5) | 31.5 ± 57.16 | 6.3 ± 13.38 | 20.0 ± 34.66 |
| AST: On IV therapy (Day 8) | -2.0 ± NA | 2.0 ± 0.00 | 2.0 ± NA |
| AST: On IV therapy (Day 11) | 2.0 ± NA | — | — |
| AST: End of IV therapy | 22.0 ± 34.71 | 13.1 ± 15.08 | 15.7 ± 23.34 |
| AST: Test of Cure | 1.5 ± 9.81 | -2.3 ± 4.54 | -1.4 ± 6.50 |
| AST: Early Follow-up | -1.2 ± 8.56 | -4.8 ± 10.34 | 1.2 ± 6.76 |
| AST: Late Follow-up | 3.3 ± 15.02 | -3.3 ± 10.07 | 3.4 ± 2.88 |
| Creatine kinase : On IV therapy (Day 5) | -76.0 ± 118.58 | -37.8 ± 46.94 | -26.0 ± 18.33 |
| Creatine kinase : On IV therapy (Day 11) | 4.0 ± NA | — | — |
| Creatine kinase : End of IV therapy | -36.0 ± 33.56 | -165.6 ± 407.70 | -23.7 ± 18.33 |
| Creatine kinase : Test of Cure | -65.3 ± 129.24 | -156.4 ± 420.00 | 18.4 ± 18.80 |
| Creatine kinase : Early Follow-up | -41.4 ± 158.04 | -218.2 ± 495.53 | -6.0 ± 30.12 |
| Creatine kinase : Late Follow-up | -37.8 ± 134.80 | -168.8 ± 448.90 | 0.2 ± 41.05 |
| GGT : On IV therapy (Day 5) | 41.7 ± 49.61 | 6.5 ± 8.27 | 24.0 ± 35.68 |
| GGT : On IV therapy (Day 11) | 22.0 ± NA | — | — |
| GGT : End of IV therapy | 35.8 ± 49.96 | 28.9 ± 39.88 | 14.0 ± 20.27 |
| GGT : Test of Cure | 16.5 ± 20.67 | 23.3 ± 24.69 | 3.6 ± 8.76 |
| GGT : Early Follow-up | -1.4 ± 36.90 | 8.3 ± 13.54 | -0.8 ± 12.15 |
| GGT : Late Follow-up | -16.7 ± 54.70 | 1.3 ± 9.58 | -3.8 ± 12.03 |
AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. For marketed medicinal products, this also includes failure to produce expected benefits (i.e., lack of efficacy), abuse or misuse. SAE is any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect or is medically significant.
| Participants | GSK2251052 750 mg | GSK2251052 1500 mg | Imipenem-Cilastatin |
|---|---|---|---|
| AE | 5 | 6 | 5 |
| SAE | 1 | 2 | 0 |
Twelve lead ECGs were obtained during the study using an ECG machine that automatically measured PR, QRS, QT, and QT corrected by Bazett's formula (QTcB), QT corrected by Fridericia's formula (QTcF) intervals. Twelve lead ECGs were performed with the participant in a semi-supine position having rested in this position for at least 10 minutes beforehand. Measurements that deviated substantially from previous readings were repeated immediately. Three measurements were taken at pre-dose on Day 1 at least 5 min apart. One additional ECG measurement was taken after completion of the first infusion of study medication. Two ECG measurements (pre and post-1st infusion of the day) were taken on Day 4 while the participant was on IV therapy. When there was an abnormal finding, two more were taken and the mean PR interval, QRS duration, QT interval and QTcB were calculated from automated ECG readings. One ECG measurement was taken at the early safety follow-up visit.
| Participants | GSK2251052 750 mg | GSK2251052 1500 mg | Imipenem-Cilastatin |
|---|---|---|---|
| Day 1: Pre-dose 1 | 0 | 4 | 2 |
| Day 1: Pre-dose 2 | 2 | 4 | 2 |
| Day 1: Pre-dose 3 | 1 | 2 | 3 |
| Day 1: Post-dose | 1 | 5 | 3 |
| Day 4 (on IV treatment): Pre-dose | 2 | 4 | 2 |
| Day 4 (on IV treatment): Post-dose | 3 | 3 | 2 |
| Early Follow-up | 0 | 3 | 2 |
| Withdrawal | 0 | 0 | 0 |
Vital sign measurements included SBP and DBP (supine or semi-supine). Measurements that deviated substantially from previous readings were repeated immediately. Mean SBP and DBP are presented.
| Millimeters of mercury (mmHg) | GSK2251052 750 mg | GSK2251052 1500 mg | Imipenem-Cilastatin |
|---|---|---|---|
| SBP: Baseline (Day 1) | 129.7 ± 29.27 | 131.9 ± 14.56 | 120.0 ± 17.64 |
| SBP: On IV therapy (Day 2) | 131.2 ± 15.20 | 125.4 ± 15.89 | 120.0 ± 19.75 |
| SBP: On IV therapy (Day 3) | 123.8 ± 15.09 | 126.6 ± 28.69 | 123.8 ± 13.88 |
| SBP: On IV therapy (Day 4) | 137.8 ± 17.61 | 127.0 ± 30.79 | 124.2 ± 17.98 |
| SBP: On IV therapy (Day 5) | 135.2 ± 27.58 | 126.6 ± 35.10 | 116.8 ± 18.42 |
| SBP: On IV therapy (Day 6) | 150.0 ± NA | 125.5 ± 34.65 | 115.0 ± 12.25 |
| SBP: On IV therapy (Day 7) | 165.0 ± NA | 125.0 ± 21.21 | 116.7 ± 20.82 |
| SBP: On IV therapy (Day 8) | 170.0 ± NA | 125.0 ± 49.50 | 110.0 ± NA |
| SBP: On IV therapy (Day 9) | 161.0 ± NA | 130.0 ± NA | 105.0 ± NA |
| SBP: On IV therapy (Day 10) | 140.0 ± NA | — | 110.0 ± NA |
| SBP: On IV therapy (Day 11) | 155.0 ± NA | — | — |
| SBP: On IV therapy (Day 12) | 140.0 ± NA | — | — |
| SBP: On IV therapy (Day 13) | 130.0 ± NA | — | — |
| SBP: On IV therapy (Day 14) | 152.0 ± NA | — | — |
| SBP: End of IV therapy | 130.0 ± 17.03 | 116.1 ± 13.93 | 117.5 ± 11.73 |
| SBP: Test of Cure | 131.3 ± 5.85 | 126.9 ± 27.17 | 126.4 ± 20.12 |
| SBP: Early Follow-up | 128.0 ± 17.03 | 120.1 ± 15.24 | 123.8 ± 13.10 |
| SBP: Late Follow-up | 148.0 ± 23.64 | 117.6 ± 21.77 | 116.6 ± 13.35 |
| DBP: Baseline (Day 1) | 68.0 ± 12.84 | 77.3 ± 9.25 | 66.5 ± 4.64 |
| DBP: On IV therapy (Day 2) | 78.3 ± 12.82 | 69.0 ± 15.61 | 70.3 ± 10.78 |
| DBP: On IV therapy (Day 3) | 77.2 ± 12.22 | 72.1 ± 15.72 | 71.2 ± 3.56 |
| DBP: On IV therapy (Day 4) | 85.5 ± 15.73 | 79.5 ± 19.41 | 69.6 ± 5.77 |
| DBP: On IV therapy (Day 5) | 83.8 ± 13.95 | 79.7 ± 21.89 | 67.0 ± 4.12 |
| DBP: On IV therapy (Day 6) | 90.0 ± NA | 81.0 ± 12.73 | 72.5 ± 15.00 |
| DBP: On IV therapy (Day 7) | 85.0 ± NA | 70.0 ± 0.00 | 67.7 ± 9.29 |
| DBP: On IV therapy (Day 8) | 90.0 ± NA | 69.0 ± 15.56 | 70.0 ± NA |
| DBP: On IV therapy (Day 9) | 95.0 ± NA | 80.0 ± NA | 65.0 ± NA |
| DBP: On IV therapy (Day 10) | 69.0 ± NA | — | 70.0 ± NA |
| DBP: On IV therapy (Day 11) | 69.0 ± NA | — | — |
| DBP: On IV therapy (Day 12) | 75.0 ± NA | — | — |
| DBP: On IV therapy (Day 13) | 80.0 ± NA | — | — |
| DBP: On IV therapy (Day 14) | 69.0 ± NA | — | — |
| DBP: End of IV therapy | 74.0 ± 9.94 | 69.4 ± 17.22 | 71.5 ± 12.42 |
| DBP: Test of Cure | 82.2 ± 5.88 | 70.6 ± 12.47 | 71.8 ± 15.14 |
| DBP: Early Follow-up | 73.8 ± 9.62 | 72.0 ± 11.72 | 68.8 ± 12.05 |
| DBP: Late Follow-up | 87.7 ± 16.18 | 67.5 ± 16.13 | 65.0 ± 5.29 |
Vital sign measurements included heart rate. Measurements that deviated substantially from previous readings were repeated immediately. Mean heart rate is presented.
| Beats per minute | GSK2251052 750 mg | GSK2251052 1500 mg | Imipenem-Cilastatin |
|---|---|---|---|
| Baseline (Day 1) | 85.8 ± 10.63 | 99.3 ± 13.78 | 87.7 ± 11.78 |
| On IV therapy (Day 2) | 78.2 ± 12.80 | 83.0 ± 18.97 | 81.5 ± 4.23 |
| On IV therapy (Day 3) | 77.8 ± 4.92 | 80.6 ± 14.79 | 81.4 ± 9.40 |
| On IV therapy (Day 4) | 78.5 ± 11.45 | 81.0 ± 10.43 | 73.6 ± 12.10 |
| On IV therapy (Day 5) | 72.3 ± 13.52 | 80.3 ± 10.55 | 68.2 ± 11.45 |
| On IV therapy (Day 6) | 89.0 ± NA | 92.0 ± 16.97 | 74.8 ± 6.70 |
| On IV therapy (Day 7) | 81.0 ± NA | 88.5 ± 16.26 | 78.3 ± 9.07 |
| On IV therapy (Day 8) | 88.0 ± NA | 87.5 ± 6.36 | 82.0 ± NA |
| On IV therapy (Day 9) | 84.0 ± NA | 80.0 ± NA | 85.0 ± NA |
| On IV therapy (Day 10) | 91.0 ± NA | — | 86.0 ± NA |
| On IV therapy (Day 11) | 100.0 ± NA | — | — |
| On IV therapy (Day 12) | 84.0 ± NA | — | — |
| On IV therapy (Day 13) | 90.0 ± NA | — | — |
| On IV therapy (Day 14) | 92.0 ± NA | — | — |
| End of IV therapy | 72.8 ± 11.82 | 82.8 ± 8.91 | 71.0 ± 7.32 |
| Test of Cure | 74.5 ± 11.86 | 73.6 ± 11.94 | 74.6 ± 15.34 |
| Early Follow-up | 72.5 ± 11.57 | 74.0 ± 14.99 | 65.8 ± 8.90 |
| Late Follow-up | 76.8 ± 13.06 | 71.8 ± 11.11 | 78.2 ± 11.19 |
Vital sign measurements included respiratory rate. Measurements that deviated substantially from previous readings were repeated immediately. Mean respiration rate are presented.
| Breaths/minute | GSK2251052 750 mg | GSK2251052 1500 mg | Imipenem-Cilastatin |
|---|---|---|---|
| Baseline (Day 1) | 17.3 ± 2.94 | 19.6 ± 3.85 | 17.3 ± 3.27 |
| On IV therapy (Day 2) | 15.0 ± 1.67 | 18.1 ± 3.68 | 16.8 ± 3.03 |
| On IV therapy (Day 3) | 14.2 ± 1.33 | 16.6 ± 3.62 | 16.8 ± 4.27 |
| On IV therapy (Day 4) | 15.5 ± 0.84 | 17.3 ± 3.99 | 17.8 ± 4.35 |
| On IV therapy (Day 5) | 14.5 ± 1.52 | 16.6 ± 3.46 | 18.8 ± 3.59 |
| On IV therapy (Day 6) | 16.0 ± NA | 17.0 ± 4.24 | 16.0 ± 4.32 |
| On IV therapy (Day 7) | 16.0 ± NA | 16.5 ± 3.54 | 17.3 ± 4.16 |
| On IV therapy (Day 8) | 16.0 ± NA | 15.0 ± 1.41 | 20.0 ± NA |
| On IV therapy (Day 9) | 14.0 ± NA | 16.0 ± NA | 22.0 ± NA |
| On IV therapy (Day 10) | 17.0 ± NA | — | 20.0 ± NA |
| On IV therapy (Day 11) | 15.0 ± NA | — | — |
| On IV therapy (Day 12) | 16.0 ± NA | — | — |
| On IV therapy (Day 13) | 14.0 ± NA | — | — |
| On IV therapy (Day 14) | 14.0 ± NA | — | — |
| End of IV therapy | 16.0 ± 2.45 | 15.8 ± 2.96 | 16.4 ± 2.19 |
| Test of Cure | 14.0 ± 1.79 | 15.5 ± 3.42 | 18.2 ± 4.15 |
| Early Follow-up | 15.3 ± 1.97 | 15.9 ± 3.52 | 16.4 ± 3.21 |
| Late Follow-up | 13.4 ± 1.95 | 16.0 ± 2.78 | 16.6 ± 3.71 |
Vital sign measurements included temperature (oral, tympanic or rectal). Measurements that deviated substantially from previous readings were repeated immediately. Temperature was assessed as normal hospital practice dictated and the maximum daily temperature was recorded in the electronic case report form (eCRF).
| Celsius | GSK2251052 750 mg | GSK2251052 1500 mg | Imipenem-Cilastatin |
|---|---|---|---|
| Baseline (Day 1) | 38.08 ± 0.741 | 38.41 ± 0.946 | 38.30 ± 0.469 |
| On IV therapy (Day 2) | 36.97 ± 1.063 | 37.30 ± 0.693 | 37.30 ± 0.860 |
| On IV therapy (Day 3) | 36.75 ± 0.706 | 36.79 ± 0.380 | 37.74 ± 0.817 |
| On IV therapy (Day 4) | 36.60 ± 0.469 | 36.71 ± 0.669 | 37.38 ± 0.986 |
| On IV therapy (Day 5) | 36.27 ± 0.378 | 36.59 ± 0.498 | 36.96 ± 0.654 |
| On IV therapy (Day 6) | 37.00 ± NA | 36.90 ± 1.273 | 36.40 ± 0.283 |
| On IV therapy (Day 7) | 36.20 ± NA | 36.95 ± 0.778 | 36.93 ± 0.416 |
| On IV therapy (Day 8) | 36.80 ± NA | 36.80 ± 0.707 | 36.50 ± NA |
| On IV therapy (Day 9) | 36.50 ± NA | 36.80 ± NA | 36.50 ± NA |
| On IV therapy (Day 10) | 37.00 ± NA | — | 36.50 ± NA |
| On IV therapy (Day 11) | 37.00 ± NA | — | — |
| On IV therapy (Day 12) | 36.80 ± NA | — | — |
| On IV therapy (Day 13) | 36.20 ± NA | — | — |
| On IV therapy (Day 14) | 36.80 ± NA | — | — |
| End of IV therapy | 36.18 ± 0.512 | 36.75 ± 0.676 | 36.38 ± 0.299 |
| Test of Cure | 36.25 ± 0.418 | 35.98 ± 0.709 | 36.14 ± 0.744 |
| Early Follow-up | 36.23 ± 0.427 | 35.99 ± 0.387 | 36.28 ± 0.606 |
| Late Follow-up | 36.40 ± 0.110 | 36.08 ± 0.512 | 36.00 ± 0.394 |
The therapeutic response was the combination of a participant's clinical and microbiological response. It was assessed at the Test of Cure visit in participants who have a qualifying Gram-negative uropathogen at Baseline and have had a minimum of 5 days of IV therapy. Therapeutic response was a measure of the overall efficacy response, and a therapeutic success referred to participants who have been deemed both a 'clinical success' and a 'microbiological success'. All other combinations (other than 'clinical success' + 'microbiological success') were deemed failures for therapeutic response.
| Participants | GSK2251052 750 mg | GSK2251052 1500 mg | Imipenem-Cilastatin |
|---|---|---|---|
| Therapeutic Success | 1 | 5 | 1 |
| Therapeutic Failure | 5 | 3 | 4 |
Hematology parameters included hematocrit. Baseline was Day 1. Change from Baseline was calculated by subtracting Baseline values from individual post-Baseline values. Mean change from Baseline up to Late follow-up visit in hematocrit are presented.
| Fraction | GSK2251052 750 mg | GSK2251052 1500 mg | Imipenem-Cilastatin |
|---|---|---|---|
| End of IV therapy | -0.0140 ± 0.06893 | -0.0155 ± 0.06930 | -0.0120 ± 0.02993 |
| Late Follow-up | 0.0373 ± 0.03079 | -0.0007 ± 0.03322 | -0.0038 ± 0.01669 |
Hematology parameters included MCH. Baseline was Day 1. Change from Baseline was calculated by subtracting Baseline values from individual post-Baseline values. Mean change from Baseline up to Late follow-up visit in MCH are presented.
| Picograms | GSK2251052 750 mg | GSK2251052 1500 mg | Imipenem-Cilastatin |
|---|---|---|---|
| End of IV therapy | -0.60 ± 0.748 | -0.60 ± 0.668 | -0.07 ± 0.628 |
| Late Follow-up | -0.85 ± 0.657 | -0.89 ± 0.573 | -0.14 ± 0.472 |
Hematology parameters included MCV. Baseline was Day 1. Change from Baseline was calculated by subtracting Baseline values from individual post-Baseline values. Mean change from Baseline up to Late follow-up visit in MCV are presented.
| Femtoliters | GSK2251052 750 mg | GSK2251052 1500 mg | Imipenem-Cilastatin |
|---|---|---|---|
| End of IV therapy | -3.0 ± 2.45 | -1.3 ± 1.98 | -1.0 ± 0.89 |
| Late Follow-up | -2.2 ± 0.98 | -1.3 ± 2.75 | -0.8 ± 1.79 |
Hematology parameters included RBC count and reticulocytes. Baseline was Day 1. Change from Baseline was calculated by subtracting Baseline values from individual post-Baseline values. Mean change from Baseline up to Late follow-up visit in RBC count and reticulocytes are presented.
| Trillion cells per liter | GSK2251052 750 mg | GSK2251052 1500 mg | Imipenem-Cilastatin |
|---|---|---|---|
| RBC: End of IV therapy | -0.10 ± 0.689 | -0.10 ± 0.707 | -0.08 ± 0.360 |
| RBC: Late Follow-up | 0.52 ± 0.366 | 0.07 ± 0.236 | 0.02 ± 0.228 |
| Reticulocytes: End of IV therapy | -0.0331 ± 0.04544 | -0.0312 ± 0.02489 | -0.0072 ± 0.02295 |
| Reticulocytes: Late Follow-up | -0.0466 ± 0.09881 | -0.0092 ± 0.03267 | 0.0080 ± 0.02577 |
Hematology parameters included hemoglobin and MCHC. Baseline was Day 1. Change from Baseline was calculated by subtracting Baseline values from individual post-Baseline values. Mean change from Baseline up to Late follow-up visit in hemoglobin and MCHC are presented.
| Gram per Liter | GSK2251052 750 mg | GSK2251052 1500 mg | Imipenem-Cilastatin |
|---|---|---|---|
| Hemoglobin: End of IV therapy | -3.0 ± 22.77 | -5.5 ± 21.36 | -2.5 ± 8.17 |
| Hemoglobin: Late Follow-up | 11.0 ± 7.24 | -2.1 ± 9.67 | -0.6 ± 4.16 |
| MCHC: End of IV therapy | 4.0 ± 3.81 | -1.8 ± 6.50 | 4.2 ± 6.74 |
| MCHC: Late Follow-up | -3.0 ± 8.44 | -5.0 ± 5.94 | 1.8 ± 8.29 |
Hematology parameters included basophils, eosinophils, lymphocytes, monocytes, platelet count, total neutrophils and WBC. Baseline was Day 1. Change from Baseline was calculated by subtracting Baseline values from individual post-Baseline values. Mean change from Baseline up to Late follow-up visit in basophils, eosinophils, lymphocytes, monocytes, platelet count, total neutrophils and WBC are presented.
| Gigacells per Liter | GSK2251052 750 mg | GSK2251052 1500 mg | Imipenem-Cilastatin |
|---|---|---|---|
| Basophils: End of IV therapy | 0.028 ± 0.0084 | 0.018 ± 0.0116 | 0.014 ± 0.0182 |
| Basophils: Late Follow-up | 0.022 ± 0.0147 | 0.020 ± 0.0163 | 0.016 ± 0.0114 |
| Eosinophils: End of IV therapy | 0.274 ± 0.1389 | 0.096 ± 0.0980 | 0.090 ± 0.0682 |
| Eosinophils: Late Follow-up | 0.093 ± 0.1488 | 0.067 ± 0.0966 | 0.086 ± 0.0385 |
| Lymphocytes: End of IV therapy | 0.580 ± 1.2076 | 0.514 ± 0.3816 | 0.596 ± 0.5140 |
| Lymphocytes: Late Follow-up | 0.687 ± 1.5191 | 0.774 ± 0.4808 | 0.436 ± 0.7578 |
| Monocytes: End of IV therapy | -0.188 ± 0.3739 | -0.256 ± 0.2015 | -0.442 ± 0.3841 |
| Monocytes: Late Follow-up | -0.380 ± 0.4553 | -0.230 ± 0.3902 | -0.186 ± 0.2103 |
| Platelet count: End of IV therapy | 141.0 ± 171.58 | 83.2 ± 139.06 | 105.4 ± 92.20 |
| Platelet count: Late Follow-up | 48.8 ± 129.10 | 45.4 ± 34.93 | 39.8 ± 35.81 |
| Total neutrophils: End of IV therapy | -8.178 ± 3.6642 | -6.695 ± 4.6214 | -4.656 ± 6.6652 |
| Total neutrophils: Late Follow-up | -6.765 ± 4.0488 | -7.737 ± 6.3494 | -7.902 ± 8.1795 |
| WBC count: End of IV therapy | -7.48 ± 4.242 | -6.30 ± 4.607 | -4.36 ± 6.696 |
| WBC count: Late Follow-up | -6.33 ± 4.918 | -7.11 ± 6.207 | -7.54 ± 8.486 |
Microbiological response involved both microbiological success and microbiological failure. A reduction in the uropathogens in the urine culture and no growth on blood culture was termed as microbiological success. Increase in the uropathogens in the urine culture and pathogens identified in the blood culture or use of antibacterials other than study treatments were classified as microbiological failures.
| Participants | GSK2251052 750 mg | GSK2251052 1500 mg | Imipenem-Cilastatin |
|---|---|---|---|
| End of IV therapy — Microbiological Success | 3 | 5 | 5 |
| End of IV therapy — Microbiological Failure | 3 | 3 | 0 |
| Test of Cure — Microbiological Success | 1 | 5 | 1 |
| Test of Cure — Microbiological Failure | 5 | 3 | 4 |
| Late Folllow-up — Microbiological Success | 2 | 6 | 1 |
| Late Folllow-up — Microbiological Failure | 4 | 2 | 4 |
Clinical response was a combination of clinical success and clinical failure. In clinical success, participants showed no signs and symptoms of pyelonephritis and lower complicated urinary tract infection and antibiotics are not used for the same. In clinical failure, there is reappearance of signs and symptoms of and lower complicated urinary tract infection and participant required antibiotics for the same.
| Participants | GSK2251052 750 mg | GSK2251052 1500 mg | Imipenem-Cilastatin |
|---|---|---|---|
| End of IV therapy — Clinical Success | 4 | 6 | 5 |
| End of IV therapy — Clinical Failure | 2 | 2 | 0 |
| Test of Cure — Clinical Success | 4 | 6 | 4 |
| Test of Cure — Clinical Failure | 2 | 2 | 1 |
| Late Follow-up — Clinical Success | 3 | 6 | 2 |
| Late Follow-up — Clinical Failure | 3 | 2 | 3 |
The therapeutic response was the combination of a participant's clinical and microbiological response. It was assessed at the Test of Cure visit in participants who have a qualifying Gram-negative uropathogen at Baseline and have had a minimum of 5 days of IV therapy. Therapeutic response was a measure of the overall efficacy response, and a therapeutic success referred to participants who have been deemed both a 'clinical success' and a 'microbiological success'. All other combinations (other than 'clinical success' + 'microbiological success') were deemed failures for therapeutic response.
| Participants | GSK2251052 750 mg | GSK2251052 1500 mg | Imipenem-Cilastatin |
|---|---|---|---|
| End of IV therapy — Therapeutic Success | 3 | 5 | 5 |
| End of IV therapy — Therapeutic Failure | 3 | 3 | 0 |
| Late Follow-up — Therapeutic Success | 2 | 6 | 1 |
| Late Follow-up — Therapeutic Failure | 4 | 2 | 4 |
The planned pharmacokinetic (PK) and PK/pharmacodynamic analyses were not performed, because the PK data was not collected.
No measurements were reported for this outcome.
The planned pharmacokinetic (PK) and PK/pharmacodynamic analyses were not performed, because the PK data was not collected.
No measurements were reported for this outcome.
The planned pharmacokinetic (PK) and PK/pharmacodynamic analyses were not performed, because the PK data was not collected.
No measurements were reported for this outcome.
The planned pharmacokinetic (PK) and PK/pharmacodynamic analyses were not performed, because the PK data was not collected.
No measurements were reported for this outcome.
The planned pharmacokinetic (PK) and PK/pharmacodynamic analyses were not performed, because the PK data was not collected.
No measurements were reported for this outcome.
The planned pharmacokinetic (PK) and PK/pharmacodynamic analyses were not performed, because the PK data was not collected.
No measurements were reported for this outcome.
The planned pharmacokinetic (PK) and PK/pharmacodynamic analyses were not performed, because the PK data was not collected.
No measurements were reported for this outcome.
The planned pharmacokinetic (PK) and PK/pharmacodynamic analyses were not performed, because the PK data was not collected.
No measurements were reported for this outcome.
The planned pharmacokinetic (PK) and PK/pharmacodynamic analyses were not performed, because the PK data was not collected.
No measurements were reported for this outcome.
Collected over Up to 28 days post-therapy. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| GSK2251052 750 mg | 0/6 (0%) | 1/6 (16.7%) | 5/6 (83.3%) |
| GSK2251052 1500 mg | 0/8 (0%) | 2/8 (25%) | 5/8 (62.5%) |
| Imipenem-Cilastatin | 0/6 (0%) | 0/6 (0%) | 5/6 (83.3%) |
| Event | GSK2251052 750 mg | GSK2251052 1500 mg | Imipenem-Cilastatin |
|---|---|---|---|
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 1/6 | 0/8 | 0/6 |
| Aspiration bronchialInvestigations | 0/6 | 1/8 | 0/6 |
| Haemoglobin decreasedInvestigations | 0/6 | 1/8 | 0/6 |
| Cardiac arrestCardiac disorders | 0/6 | 1/8 | 0/6 |
| Escherichia bacteraemiaInfections and infestations | 0/6 | 1/8 | 0/6 |
| Event | GSK2251052 750 mg | GSK2251052 1500 mg | Imipenem-Cilastatin |
|---|---|---|---|
| DizzinessNervous system disorders | 1/6 | 0/8 | 2/6 |
| HeadacheNervous system disorders | 0/6 | 0/8 | 2/6 |
| NauseaGastrointestinal disorders | 0/6 | 2/8 | 1/6 |
| Alanine aminotransferase increasedInvestigations | 1/6 | 2/8 | 0/6 |
| Abdominal pain upperGastrointestinal disorders | 0/6 | 0/8 | 1/6 |
| DyspepsiaGastrointestinal disorders | 0/6 | 0/8 | 1/6 |
| Rectal haemorrhageGastrointestinal disorders | 0/6 | 0/8 | 1/6 |
| ParaesthesiaNervous system disorders | 1/6 | 0/8 | 0/6 |
| PharyngitisInfections and infestations | 1/6 | 0/8 | 1/6 |
| Oral herpesInfections and infestations | 1/6 | 0/8 | 0/6 |
| Age, Continuous(Years) | GSK2251052 750 mg | GSK2251052 1500 mg | Imipenem-Cilastatin | Total |
|---|---|---|---|---|
| Mean | 55.7 ± 13.60 | 50.4 ± 24.45 | 48.0 ± 17.48 | 51.3 ± 18.95 |
| Sex: Female, Male(Participants) | GSK2251052 750 mg | GSK2251052 1500 mg | Imipenem-Cilastatin | Total |
|---|---|---|---|---|
| Female | 3 | 4 | 3 | 10 |
| Male | 3 | 4 | 3 | 10 |
| Race (NIH/OMB)(Participants) | GSK2251052 750 mg | GSK2251052 1500 mg | Imipenem-Cilastatin | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 1 | 2 |
| Asian | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 1 | 0 | 1 |
| White | 6 | 6 | 5 | 17 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
Ran from Jun 2011 to primary completion in Mar 2012, 8 months.
Results were first posted in Sep 2017, 5 years 6 months after primary completion. A results delay was requested in Nov 2012.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Epetraborole